Baird Reiterates an 'Outperform' on AMAG Pharmaceuticals (AMAG); Four Plus Two Equals Five? We Don't Think So - Staying with it Here

Baird reiterates an 'Outperform' on AMAG Pharmaceuticals (NASDAQ: AMAG), PT $22.

Baird analyst says, "While we are not yet entirely comfortable defending the AMAG / Allos Therapeutics (Nasdaq: ALTH) deal, we do think yesterday's reaction - erasing ~$70M of market cap from the combined entities - was an overreaction. In that we think our long-term thesis (Feraheme recovery, compelling valuation, excessive negative sentiment) remains intact, we are sticking with it here, despite what is undeniably now significantly heightened execution risk."

For more ratings news on AMAG Pharmaceuticals click here and for the rating history of AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $19.07 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Wolverine World Wide (WWW) PT Raised to $31 at UBS on Growth, EPS Upside Potential